Splenectomy in myelofibrosis with myeloid metaplasia: a single-institution experience with 223 patients.
about
Emerging treatment options for myelofibrosis: focus on pacritinibBacterial Infections Following Splenectomy for Malignant and Nonmalignant Hematologic DiseasesAllogeneic stem cell transplant for myelofibrosis patients over age 60: likely impact of the JAK2 inhibitorsRuxolitinib: a new JAK1/2 inhibitor that offers promising options for treatment of myelofibrosis.Emerging drugs for myelofibrosis.Splenectomy in patients with myeloproliferative neoplasms: efficacy, complications and impact on survival and transformation.Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controlsOutcome of transplantation for myelofibrosis.How to manage the transplant question in myelofibrosis.Real-World Assessment of Clinical Outcomes in Patients with Lower-Risk Myelofibrosis Receiving Treatment with Ruxolitinib.New Strategies in Myeloproliferative Neoplasms: The Evolving Genetic and Therapeutic Landscape.Portal hypertension secondary to myelofibrosis with myeloid metaplasia: a study of 13 cases.Allogeneic hematopoietic cell transplantation for patients with myelofibrosisTherapeutic potential of Janus-activated kinase-2 inhibitors for the management of myelofibrosisDefinition and management of ruxolitinib treatment failure in myelofibrosis.How I treat splenomegaly in myelofibrosis.Primary myelofibrosis: current therapeutic options.Emerging therapeutic options for myelofibrosis: a Canadian perspective.Imatinib and tyrosine kinase inhibition, in the management of BCR-ABL negative myeloproliferative disorders.Recent advances in the diagnosis and management of primary myelofibrosis.
P2860
Q26745939-5E48F1D1-704C-4F34-A649-E0599F6D0996Q26778773-0CA80CD4-FDAD-4143-B043-2B723BC40763Q26863610-421A8B6E-0CAD-4512-BFC7-79DF439F35CDQ33397219-CDCBE68B-20E6-43ED-A2A5-0957DCC1BA2AQ33404574-BE7CEEF2-AD5A-4B10-87F9-E80BE8FDED6FQ33406990-2242669B-EAA9-4E2E-A4AB-A1B3817BEF09Q33843390-6E546E48-112D-4759-9021-D787EDD39842Q34015474-0E9AA71E-3CC6-42A6-A138-6B7C9CBE66C3Q35865676-948E5A63-8EBD-486D-A401-DBCB2654B3ECQ36305314-8DBABFA3-4299-496A-B15D-E14ABA0313ABQ36782943-F1B4B2DD-58A0-4712-B65E-603D11288108Q37250357-BE4A9584-12B4-42CA-A64D-447F50997225Q37495397-C3437421-6448-4AB5-9590-E0AFE30680A8Q37705695-0E53595F-FD38-464E-9299-244265A43C2CQ38287012-287E9863-45AD-42E2-A438-D81D3016EADCQ39244371-BFB634AD-F1A1-4FFC-924E-31D110E1A2E7Q41186952-492BF6DA-926E-4AF1-AC69-AABE62DE510AQ41627599-7C115DCA-5BB5-403D-93EC-708F7DC29776Q42201127-B7F96BC0-CABA-458E-80B9-CDCC9A4223DEQ54980872-DC6DA419-04B9-40A5-92E2-74AEE0751109
P2860
Splenectomy in myelofibrosis with myeloid metaplasia: a single-institution experience with 223 patients.
description
2000 nî lūn-bûn
@nan
2000 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Splenectomy in myelofibrosis w ...... experience with 223 patients.
@ast
Splenectomy in myelofibrosis w ...... experience with 223 patients.
@en
Splenectomy in myelofibrosis w ...... experience with 223 patients.
@nl
type
label
Splenectomy in myelofibrosis w ...... experience with 223 patients.
@ast
Splenectomy in myelofibrosis w ...... experience with 223 patients.
@en
Splenectomy in myelofibrosis w ...... experience with 223 patients.
@nl
prefLabel
Splenectomy in myelofibrosis w ...... experience with 223 patients.
@ast
Splenectomy in myelofibrosis w ...... experience with 223 patients.
@en
Splenectomy in myelofibrosis w ...... experience with 223 patients.
@nl
P2093
P1433
P1476
Splenectomy in myelofibrosis w ...... n experience with 223 patients
@en
P2093
Nagorney DM
Schroeder G
Silverstein MN
P304
P407
P577
2000-04-01T00:00:00Z